Alexander Knuth

List of Publications by Year
in descending order

167 papers	11,123 citations	41344 49 h-index	37204 96 g-index
170 all docs	170 docs citations	170 times ranked	12808 citing authors

#	Article	IF	Citations
1	Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study. Oncology, 2021, 99, 300-309.	1.9	10
2	The effect of protein mutations on drug binding suggests ensuing personalised drug selection. Scientific Reports, 2021, 11, 13452.	3.3	11
3	Virusâ€like particles for vaccination against cancer. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1579.	6.1	74
4	Vaccination Against Amyloidogenic Aggregates in Pancreatic Islets Prevents Development of Type 2 Diabetes Mellitus. Vaccines, 2020, 8, 116.	4.4	17
5	Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation. Leukemia and Lymphoma, 2019, 60, 685-695.	1.3	1
6	Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. Frontiers in Immunology, 2019, 10, 1015.	4.8	39
7	Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. , 2019, 7, 114.		41
8	Î²₆â€integrin serves as a novel serum tumor marker for colorectal carcinoma. International Journal of Cancer, 2019, 145, 678-685.	5.1	42
9	Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. BMC Cancer, 2018, 18, 72.	2.6	26
10	Phase I study of a chloroquineâ€“gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 1005-1012.	2.3	61
11	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. Journal of Gastrointestinal Oncology, 2017, 8, 1079-1099.	1.4	34
12	Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers. Cancer Immunology Research, 2016, 4, 18-25.	3.4	18
13	Precision Medicine and Non-Colorectal Cancer Liver Metastases: Fiction or Reality?. Visceral Medicine, 2015, 31, 434-439.	1.3	1
14	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	4.6	119
15	Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer. Cancer Immunology Research, 2015, 3, 1279-1288.	3.4	3
16	Complement Is a Central Mediator of Radiotherapy-Induced Tumor-Specific Immunity and Clinical Response. Immunity, 2015, 42, 767-777.	14.3	135
17	Chromosomal aberrations of cancerâ€“testis antigens in myeloma patients. Hematological Oncology, 2015, 33, 159-163.	1.7	1
18	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395

#	Article	IF	Citations
19	Cancer testis antigen expression in testicular germ cell tumorigenesis. Modern Pathology, 2014, 27, 899-905.	5.5	22
20	Simultaneous cytoplasmic and nuclear protein expression of melanoma antigenâ€A family and NYâ€ESOâ€1 cancerâ€testis antigens represents an independent marker for poor survival in head and neck cancer. International Journal of Cancer, 2014, 135, 1142-1152.	5.1	46
21	Imagine a world without cancer. BMC Cancer, 2014, 14, 186.	2.6	12
22	Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology, Immunotherapy, 2014, 63, 381-394.	4.2	84
23	Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates. Cancer Immunology Research, 2014, 2, 404-409.	3.4	10
24	Challenges In Adapting International Best Practices In Cancer Prevention, Care, And Research For Qatar. Health Affairs, 2014, 33, 1635-1640.	5.2	1
25	Innovation Can Improve And Expand Aspects Of End-Of-Life Care In Low- And Middle-Income Countries. Health Affairs, 2014, 33, 1612-1619.	5.2	15
26	Targeted Exome Sequencing Identifies Novel Mutations in Familial Myeloproliferative Neoplasms Patients in the State of Qatar. Blood, 2014, 124, 5570-5570.	1.4	2
27	Neutrophil expression of ICAM1, CXCR1, and VEGFR1 in patients with breast cancer before and after adjuvant chemotherapy. Anticancer Research, 2014, 34, 4693-9.	1.1	5
28	Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 565-574.	2.8	13
29	Aldara activates TLR7-independent immune defence. Nature Communications, 2013, 4, 1560.	12.8	211
30	Spontaneous Peripheral T-cell Responses toward the Tumor-Associated Antigen Cyclin D1 in Patients with Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2013, 1, 288-295.	3.4	7
31	RP1 Is a Phosphorylation Target of CK2 and Is Involved in Cell Adhesion. PLoS ONE, 2013, 8, e67595.	2.5	7
32	Computed Tomographic Perfusion Imaging for the Prediction of Response and Survival to Transarterial Radioembolization of Liver Metastases. Investigative Radiology, 2013, 48, 787-794.	6.2	42
33	Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature. Clinical Cancer Research, 2013, 19, 4843-4853.	7.0	60
34	Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. OncoImmunology, 2013, 2, e23562.	4.6	138
35	Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial. Journal of Cancer, 2013, 4, 597-605.	2.5	39
36	Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancreas in an Adolescent Patient. Case Reports in Oncology, 2013, 6, 497-503.	0.7	12

#	Article	IF	Citations
37	Abstract B1: Radiotherapy promotes tumor-specific effector CD8+ T cells via DC activation.. , 2013, , .		16
38	Abstract A18: Mouse models of autochthonous cancer to study local immune subversion.. , 2013, , .		0
39	Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. Swiss Medical Weekly, 2013, 143, w13791.	1.6	3
40	A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immunity, 2013, 13, 3.	3.2	10
41	NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. Cancer Immunity, 2013, 13, 12.	3.2	15
42	Status of hepatocellular carcinoma in Gulf region. Chinese Clinical Oncology, 2013, 2, 42.	1.2	4
43	A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma. Oncology, 2012, 82, 333-340.	1.9	29
44	Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial. Oncology, 2012, 83, 1-9.	1.9	41
45	Radiotherapy supports protective tumor-specific immunity. OncoImmunology, 2012, 1, 1610-1611.	4.6	27
46	Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation. Journal of Immunology, 2012, 189, 558-566.	0.8	363
47	Quantitative Perfusion Analysis of Malignant Liver Tumors. Investigative Radiology, 2012, 47, 18-24.	6.2	52
48	Automated tube potential selection for standard chest and abdominal CT in follow-up patients with testicular cancer: comparison with fixed tube potential. European Radiology, 2012, 22, 1937-1945.	4.5	49
49	Liver Perfusion Imaging in Patients with Primary and Metastatic Liver Malignancy. Academic Radiology, 2012, 19, 613-621.	2.5	20
50	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. Cancer Research, 2012, 72, 1672-1682.	0.9	46
51	Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. Lung Cancer, 2012, 76, 118-122.	2.0	18
52	Messenger RNA vaccination and B-cell responses in NSCLC patients.. Journal of Clinical Oncology, 2012, 30, 2573-2573.	1.6	9
53	The discovery of cancer/testis antigens by autologous typing with T cell clones and the evolution of cancer vaccines. Cancer Immunity, 2012, 12, 6.	3.2	8
54	MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors. Modern Pathology, 2011, 24, 829-835.	5.5	39

#	Article	IF	Citations
55	The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. Vaccine, 2011, 29, 3832-3836.	3.8	16
56	Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients. PLoS ONE, 2011, 6, e21418.	2.5	42
57	Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Annals of Hematology, 2011, 90, 89-94.	1.8	15
58	Performance of different data sources in identifying adverse drug events in hospitalized patients. European Journal of Clinical Pharmacology, 2011, 67, 909-918.	1.9	4
59	Gemcitabine depletes regulatory Tâ€cells in human and mice and enhances triggering of vaccineâ€specific cytotoxic Tâ€cells. International Journal of Cancer, 2011, 129, 832-838.	5.1	69
60	Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer. Case Reports in Oncology, 2011, 4, 16-18.	0.7	15
61	Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen NaÃ¯ve Prostate Cancer Patients. Clinical Cancer Research, 2011, 17, 861-870.	7.0	63
62	MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer. PLoS ONE, 2011, 6, e21366.	2.5	47
63	Î³-Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo. PLoS ONE, 2011, 6, e28217.	2.5	127
64	Abstract 5530: Evidence for immunological pressure and escape from longitudinal analysis of the expression of and immune responses against NY-ESO-1 in a patient with metastatic melanoma. , 2011, , .		0
65	Abstract 5516: Therapeutic vaccination with the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. , 2011, , .		0
66	Abstract 4741: Therapeutic efficacy of a human-derived antibody against cancer-testis antigen NY-ESO-1. , 2011, , .		0
67	Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. Swiss Medical Weekly, 2011, 141, w13203.	1.6	8
68	Increased Bone Marrow Activity on F-18-FDG PET/CT in Granulocyte Colony Stimulating Factor Producing Anaplastic Thyroid Carcinoma. Clinical Nuclear Medicine, 2010, 35, 103-104.	1.3	17
69	Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients. Journal of Immunotherapy, 2010, 33, 848-858.	2.4	131
70	Particle size and activation threshold: a new dimension of danger signaling. Blood, 2010, 115, 4533-4541.	1.4	103
71	Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Annals of Hematology, 2010, 89, 783-787.	1.8	21
72	Frequent expression of the breast differentiation antigen NY-BR-1 in mammary and extramammary Paget's disease. Pathology International, 2010, 60, 726-734.	1.3	16

#	Article	IF	Citations
73	Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism, 2010, 62, 1224-1235.	6.7	65
74	NYâ€ESOâ€1 protein glycosylated by yeast induces enhanced immune responses. Yeast, 2010, 27, 919-931.	1.7	5
75	Quantitative Computed Tomography Liver Perfusion Imaging Using Dynamic Spiral Scanning With Variable Pitch. Investigative Radiology, 2010, 45, 419-426.	6.2	71
76	Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas. Clinical Cancer Research, 2010, 16, 3562-3570.	7.0	51
77	Cryptic Epitopes Induce High-Titer Humoral Immune Response in Patients with Cancer. Journal of Immunology, 2010, 185, 3095-3102.	0.8	10
78	Fine analysis of spontaneous MAGE-C1/CT7â€“specific immunity in melanoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15187-15192.	7.1	21
79	Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation. Oncology, 2010, 79, 93-97.	1.9	7
80	Developments in Cancer Immunotherapy. Digestive Diseases, 2010, 28, 51-56.	1.9	10
81	Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer â€" A phase II study. Gynecologic Oncology, 2009, 112, 384-388.	1.4	21
82	Frequent expression of the novel cancer testis antigen MAGEâ€C2/CTâ€10 in hepatocellular carcinoma. International Journal of Cancer, 2009, 124, 352-357.	5.1	63
83	Targeted therapy of renal cell carcinoma: Synergistic activity of cG250â€TNF and IFNg. International Journal of Cancer, 2009, 125, 115-123.	5.1	37
84	Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunology, Immunotherapy, 2009, 58, 325-338.	4.2	27
85	Rational development of high-affinity T-cell receptor-like antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5784-5788.	7.1	109
86	Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. Cancer Immunity, 2009, 9, 2.	3.2	5
87	Distinct expression patterns of the immunogenic differentiation antigen NYâ€BRâ€1 in normal breast, testis and their malignant counterparts. International Journal of Cancer, 2008, 122, 1585-1591.	5.1	20
88	Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients. Cancer Immunology, Immunotherapy, 2008, 57, 871-881.	4.2	23
89	Targeted therapeutic approach for an anaplastic thyroid cancer inÂvitro and inÂvivo. Cancer Science, 2008, 99, 1847-1852.	3.9	18
90	New Derivatives of Vitamin B12 Show Preferential Targeting of Tumors. Cancer Research, 2008, 68, 2904-2911.	0.9	117

#	Article	IF	Citations
91	Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology, 2008, 26, 1435-1442.	1.6	689
92	Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head. Journal of Clinical Oncology, 2008, 26, 2526-2531.	1.6	174
93	Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. European Journal of Dermatology, 2008, 18, 566-70.	0.6	25
94	Infarction-Like Electrocardiographic Changes Due to a Myocardial Metastasis From a Primary Lung Cancer. Circulation, 2007, 115, e320-1.	1.6	3
95	Treatment of POEMS syndrome with bevacizumab. Haematologica, 2007, 92, 1438-1439.	3.5	67
96	An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer. Oncology Research and Treatment, 2007, 30, 355-360.	1.2	25
97	NY-BR-1 is a Differentiation Antigen of the Mammary Gland. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 77-83.	1.2	33
98	Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin. Journal of Immunology, 2007, 178, 320-329.	0.8	309
99	NY-ESO-1 protein expression in primary breast carcinoma and metastasesâ€"correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. International Journal of Cancer, 2007, 120, 2411-2417.	5.1	65
100	The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. International Journal of Cancer, 2007, 120, 2635-2642.	5.1	31
101	Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. International Journal of Cancer, 2007, 121, 2042-2048.	5.1	25
102	NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2007, 56, 1723-1731.	4.2	55
103	Expansion of Umbilical Cord Blood Hematopoietic Stem Cells for Clinical Use.. Blood, 2007, 110, 4049-4049.	1.4	0
104	LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immunity, 2007, 7, 16.	3.2	41
105	A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Journal of Immunology, 2007, 178, 2617-21.	0.8	38
106	NYâ€ESOâ€1: Review of an Immunogenic Tumor Antigen. Advances in Cancer Research, 2006, 95, 1-30.	5.0	311
107	Potential use of humanized antibodies in the treatment of breast cancer. Expert Review of Anticancer Therapy, 2006, 6, 1065-1074.	2.4	17
108	Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunology, Immunotherapy, 2006, 56, 249-258.	4.2	17

#	Article	IF	Citations
109	Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. International Journal of Cancer, 2006, 118, 668-674.	5.1	11
110	Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m² Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer. Oncology, 2006, 70, 141-146.	1.9	51
111	Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases. Clinical Cancer Research, 2006, 12, 2745-2751.	7.0	42
112	Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14453-14458.	7.1	202
113	Structure-Activity Profiles of Ab-Derived TNF Fusion Proteins. Journal of Immunology, 2006, 177, 2423-2430.	0.8	31
114	Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients. Journal of Immunology, 2006, 177, 8212-8218.	0.8	24
115	Differentiation of Non-Adherent Hematopoietic Stem Cells from Umbilical Cord Blood Cells into Adherent Hepatocytic Lineage.. Blood, 2006, 108, 2578-2578.	1.4	1
116	Cancer immunity hits multiple myeloma. Blood, 2005, 105, 3765-3766.	1.4	1
117	Antibodies and vaccinesâ€“hope or illusion?. Breast, 2005, 14, 631-635.	2.2	20
118	Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients. International Journal of Cancer, 2005, 117, 800-806.	5.1	20
119	Undifferentiated sarcoma arising in the brain, 23Âyears after curative treatment of an ependymoma. Journal of Neuro-Oncology, 2005, 72, 239-239.	2.9	0
120	Intratumoral T-Cell Infiltrates and MHC Class I Expression in Patients with Stage IV Melanoma. Cancer Research, 2005, 65, 3937-3941.	0.9	56
121	Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Research, 2005, 7, R617-26.	5.0	84
122	Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immunity, 2005, 5, 11.	3.2	39
123	Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunology, Immunotherapy, 2004, 53, 144-147.	4.2	48
124	Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. Journal of Immunological Methods, 2003, 278, 57-66.	1.4	46
125	Antigen-specific immunotherapy and cancer vaccines. International Journal of Cancer, 2003, 106, 817-820.	5.1	83
126	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8862-8867.	7.1	179

#	Article	IF	Citations
127	Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs. Journal of Immunology, 2003, 170, 1191-1196.	0.8	50
128	Antibody and T-cell responses to the NY-ESO-1 antigen. , 2003, , 191-197.		0
129	Impact of Antigen Presentation on TCR Modulation and Cytokine Release: Implications for Detection and Sorting of Antigen-Specific CD8+ T Cells Using HLA-A2 Wild-Type or HLA-A2 Mutant Tetrameric Complexes. Journal of Immunology, 2002, 168, 2766-2772.	0.8	8
130	CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11813-11818.	7.1	83
131	Identification of cancer/testis genes by database mining and mRNA expression analysis. International Journal of Cancer, 2002, 98, 485-492.	5.1	111
132	Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue. International Journal of Cancer, 2002, 97, 64-71.	5.1	16
133	Clinical cancer vaccine trials. Current Opinion in Immunology, 2002, 14, 178-182.	5.5	115
134	Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Research, 2002, 62, 4041-7.	0.9	149
135	Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. Cancer Immunity, 2002, 2, 5.	3.2	31
136	Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immunity, 2002, 2, 12.	3.2	14
137	Antigen recognition by T cells: a strong sense of structure. Trends in Immunology, 2001, 22, 599-601.	6.8	3
138	Vaccination for Malignant Melanoma: Recent Developments. Oncology, 2001, 60, 1-7.	1.9	65
139	Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL. Journal of Immunology, 2000, 165, 948-955.	0.8	161
140	Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101â€“0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1â€“Expressing Melanoma. Journal of Experimental Medicine, 2000, 191, 625-630.	8.5	196
141	Clonal expansion of melan a-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. International Journal of Cancer, 2000, 86, 538-547.	5.1	105
142	Cancer immunotherapy in clinical oncology. Cancer Chemotherapy and Pharmacology, 2000, 46, S46-S51.	2.3	27
143	CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer and Metastasis Reviews, 1999, 18, 143-150.	5.9	52
144	Induction of immunogenicity of a human renal-cell carcinoma cell line byTAP1-gene transfer. , 1999, 81, 125-133.		32

#	Article	IF	Citations
145	Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A. , 1999, 81, 979-984.		13
146	Humoral immune responses of cancer patients against â€œCancer-Testisâ€•antigen NY-ESO-1: Correlation with clinical events. , 1999, 84, 506-510.		194
147	Antigens recognized by autologous antibody in patients with renal-cell carcinoma. , 1999, 83, 456-464.		146
148	Strong Immunogenic Potential of a B7 Retroviral Expression Vector: Generation of HLA-B7-Restricted CTL Response Against Selectable Marker Genes. Human Gene Therapy, 1998, 9, 53-62.	2.7	31
149	A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens. Journal of Experimental Medicine, 1998, 187, 1349-1354.	8.5	642
150	Simultaneous Humoral and Cellular Immune Response against Cancerâ€“Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2â€“binding Peptide Epitopes. Journal of Experimental Medicine, 1998, 187, 265-270.	8.5	668
151	Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. International Journal of Cancer, 1997, 71, 142-147.	5.1	287
152	SSX: A multigene family with several members transcribed in normal testis and human cancer. International Journal of Cancer, 1997, 72, 965-971.	5.1	190
153	Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated antigens. , 1996, 66, 162-169.		200
154	Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variantsin vivo. , 1996, 66, 470-476.		243
155	Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptidesin vivo. , 1996, 67, 54-62.		261
156	Generation of cytotoxic Tâ€cell responses with synthetic melanomaâ€associated peptides in vivo: Implications for tumor vaccines with melanomaâ€associated antigens. International Journal of Cancer, 1996, 66, 162-169.	5.1	6
157	Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. Cancer Genetics and Cytogenetics, 1995, 80, 138-149.	1.0	35
158	Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunology, Immunotherapy, 1994, 39, 93-99.	4.2	42
159	Cellular immune response to human renal-cell carcinomas: Definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-Lymphocyte (CTL) clones. International Journal of Cancer, 1994, 59, 837-842.	5.1	55
160	Effect of ursodeoxycholic acid on intracellular pH in a bile duct epithelium-like cell line. Hepatology, 1994, 19, 145-154.	7.3	24
161	Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunology, Immunotherapy, 1994, 39, 93-99.	4.2	3
162	Lysis of human pancreatic adenocarcinoma cells by autologous hla-class I-restricted cytolytic T-lymphocyte (CTL) clones. International Journal of Cancer, 1993, 54, 636-644.	5.1	46

#	Article	IF	Citations
163	Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3. International Journal of Cancer, 1993, 55, 465-470.	5.1	8
164	Cellular and humoral immune responses against cancer: implications for cancer vaccines. Current Opinion in Immunology, 1991, 3, 659-664.	5.5	22
165	Response to monocolonal antibodies in melanoma: Specific or non-specific?. European Journal of Cancer & Clinical Oncology, 1986, 22, 1285-1288.	0.7	2
166	Hepatocellular carcinoma after thorotrast exposure: Establishment of a new cell line (Mz-Hep-1). Hepatology, 1985, 5, 1112-1119.	7.3	21
167	Target level blocking of T-cell cytotoxicity for human malignant melanoma by monoclonal antibodies. Cellular Immunology, 1984, 83, 398-403.	3.0	12